Scale Up

Mar 02, 2009
BioPharm International
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Mar 02, 2009
BioPharm International
New techniques can greatly improve the MAb purification process.
Mar 02, 2009
BioPharm International
In three non-affinity purification processes based on cation exchange capture with high binding capacity, applying a host cell protein exclusion strategy enabled robust scale up and better economics.
Mar 02, 2009
BioPharm International
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Mar 02, 2009
BioPharm International
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Mar 02, 2009
BioPharm International
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Mar 01, 2009
BioPharm International
By BioPharm International Editors
Data on the performance and variability of different formats.
Mar 01, 2009
BioPharm International
A close-up look at Pfizer's biotherapeutics plant in Shanbally, Ireland.
Mar 01, 2009
BioPharm International
Robust packing procedures can improve process performance and increase resin lifetime.
Jan 02, 2009
BioPharm International
With virus-based production, vaccines can be available in 10-12 weeks.
native1_300x100
lorem ipsum